Physician profile
Allyson Harrell
NPI 1073854956
$4,484.58
in general payments reported to CMS, 2019-2025
22 companies · $877 in 2025
The $877 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $907 · 2022: $941 · 2023: $863 · 2024: $897 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,372.53 |
| Education | $263.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $719.41 | 2021-2025 | Winlevi, Ilumya |
| Abbvie INC. | $617.77 | 2021-2025 | |
| Genzyme Corporation | $478.49 | 2021-2025 | |
| Janssen Biotech, INC. | $430.44 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $363.14 | 2021-2025 | |
| Amgen INC. | $253.87 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $248.92 | 2021-2025 | |
| Incyte Corporation | $223.69 | 2021-2025 | Opzelura |
| Almirall LLC | $204.70 | 2021-2025 | Klisyri, Seysara |
| Leo Pharma INC. | $177.23 | 2021-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $158.36 | 2021-2023 | Libtayo, Dupixent |
| Ucb, INC. | $121.34 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $94.92 | 2021-2024 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.90 | 2021-2024 | Jublia, Arazlo, Cabtreo |
| Dermavant Sciences, INC. | $69.10 | 2022-2023 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $54.87 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.02 | 2023 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.61 | 2024 | Spevigo |
| Mayne Pharma Commercial LLC | $34.15 | 2023 | |
| Lilly USA, LLC | $28.89 | 2021 | |
| Journey Medical Corporation | $26.09 | 2022 | |
| Organon LLC | $22.67 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.